J. Jankovic, A. H. Rajput, M. P. McDermott, and D. P. Perl, “The evolution of diagnosis in early Parkinson disease,” Arch. Neurol., 57, No. 3, 369–372 (2000).
2.M. Canesi, R. Benti, G. Marotta, et al., “Striatal dopamine transporter binding in patients with Parkinson’s disease and severe occupational hydrocarbon exposure,” Eur. J. Neurol., 14, No. 3, 297–299 (2007).
3.S. Fahn and D. Sulzer, “Neurodegeneration and neuroprotection in Parkinson Disease,” NeuroRx, 1, No. 1, 139–154 (2004).
4.I. T. Niculescu (ed.), Pathomorphology of the Nervous System [In Russian], Medical Publishing House, Bucharest, 987p. (1963).
5.M.-F. Chesselet and F. Richter, “Modelling of Parkinson’s disease in mice,” Lancet Neurol., 10, No. 12, 1108–1118 (2011); doi: https://doi.org/10.1016/S1474-4422(11)70227-7.
6.A. H. Schapira, “Etiology and pathogenesis of Parkin- son disease,” Neurol. Clin., 27, No. 3, 583–603 (2009).
7.D. J. Brooks, “Neuroimaging in Parkinson’s disease,” NeuroRx, 1, No. 2, 243–254 (2004).
8.B. A. Faucheux, M.-E. Martin, C. Beaumont, et al., “Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease,” J. Neurochem., 86, No. 5, 1 142–1148 (2003).
9.G. Ebersbach, C. Moreau, F. Gandor et al., “Clinical syndromes: Parkinsonian gait,” Mov. Disord., 28, No. 11, 1552–1559 (2013).
10.J. P. Bolam and E. K. Pissadaki, “Living on the edge with too many mouths to feed: why dopamine neurons die,” Mov. Disord., 27, No. 12, 1478–1483 (2012).
11.T. A. Yacoubian and D. G. Standaert, “Targets for neuroprotection in Parkinson’s disease,” Biochim. Biophys. Acta, 1792, No. 7, 676–687 (2009).
12.C. C. Stichel, X.-R. Zhu, V. Bader, et al., “Mono- and double-mutant mouse models of Parkinson’s disease display severe mitochondrial damage,” Hum. Mol. Genet., 16, No. 20, 2377–2393 (2007).
13.S. Schmidt, B. Linnartz, S. Mendritzki, et al., “Genetic mouse models for Parkinson’s disease display severe pathology in glial cell mitochondria,” Hum. Mol. Genet., 20, No. 6, 1 197–1211 (2011).
14.A. A. Galoyan, V. S. Aprikian, K. A. Markossian, and B. Ya. Gurvitz, “Neurosecretion of cytokines by magnocellular cells of hypothalamus,” Neurochemistry (RAS & NAS RA), 15, No. 4, 361-372 (1998).
15.A. A. Galoyan, J. S. Sarkissian, T. K. Kipriyan, et al., “Protective effect of the new hypothalamic peptides against cobra venom and trauma-induced neuronal injury,” Neurochem. Res., 26, No. 8–9, 1023–1038 (2001).
16.K. Yenkoyan, K. Fereshetyan, S. Matinyan, et al., “The role of monoamines in the development of Alzheimer’s disease and neuroprotective effect of a proline rich polypeptide,” Prog. Neuropsychopharmacol. Biol. Psychiatry, 86, 76–82 (2018).
17.V. S. Aprikian and A. А. Galoyan, “Immunoprotective properties of a novel hypothalamic polypeptide in bacterial pathologies [In Russian],” Med. Sci. Armenia, 39, No. 2, 23–29 (1999).
18.A. Akopian and A. Galoyan, “Effect of hypothalamic proline-rich-polypeptide on voltage-gated Ca2+ currents in retinal ganglion cells,” Neurochem. Res., 28, No. 12, 1867–1871 (2004).
19.R. M. Srapionyan, Z. Ch. Paronyan, F. M. Sahakyan, and A. A. Galoyan, “Study of the role of proline rich peptide in the regulation of the hemostasis system [In Russian],” Neirokhimia, 31, No. 1, 54–57 (2014).
20.G. Faure, “Natural inhibitors of toxic phospholipases A2,” Biochimie, 82, No. 9–10, 833–840 (2000).
21.S. K. Costa, L. C. Esquisatto, E. Camargo, et al., “Comparative effect of Phoneutria nigriventer spider venom and capsaicin on the rat paw oedema,” Life Sci., 69, No. 13, 1573–1585 (2001).
22.N. S. Cook (ed.), Potassium Channels: Structure, Classification, Function and Therapeutic Potential, Ellis Horwood Ltd., Chichester, 1990.
23.L. Harvey, “Defining and measuring employability,” Quality Higher Educ., 7, No. 2, 97–109 (2001).
24.C. G. Moreira, J. K. Barbiero, D. Ariza, et al., “Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: A new approach for an old neurotoxin,” Neurotox. Res., 21, No. 3, 291–301 (2012).
25.G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates (5th ed.), Academic Press, New York (2005), 367p.
26.I. B. Meliksetyan, “The revealing of Ca2+-dependent activity of acid phosphatase in cell structures of rat brain [In Russian],” Morfologia, 131, No. 2, 77–80 (2007).
27.I. Ch. Sharova, Invertebrate Zoology [In Russian], Humanist Publishing Center VLADOS, Moscow, 592 pp. (2002).
28.W. J. Streit, J. R. Conde, S. E. Fendrick, et al., “Role of microglia in the central nervous system’s immune response,” Neurol Res., 27, No. 7, 685–691 (2005).
29.M. E. Kalaitzakis, M. B. Graeber, S. M. Gentleman, and R. K. B. Pearce, “Controversies over the staging of alpha-synuclein pathology in Parkinson’s disease,” Acta Neuropathol., 116, No. 1, 125–128 (2008).
30.F. L. Episcopo, C. Tirolo, N. Testa, et al., “Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson’s disease: focus on endogenous neurorestoration,” Curr. Aging Sci., 6, No. 1, 45–55 (2013).
31.P. M. Rappold and K. Tieu, “Astrocytes and therapeutics for Parkinson’s disease,” Neurotherapeutics, 7, No. 4, 413–423 (2010).
32.C. M. Tanner, F. Kamel, G. W. Ross, et al. “Rotenone, paraquat, and Parkinson’s disease,” Environ. Health Perspect., 119, No. 6, 866–872 (201 1).
33.A. V. Osipov, Study of Cobras Underrepresented in Venom Proteins of New Structural Types [In Russian], Author’s thesis for the degree of Candidate of Chemical Sciences, Moscow (2014).
34.A. A. Galoyan, Biochemistry of Novel Cardioactive Hormones and Immunomodulators of the Functional System Neurosecretory Hypothalamus – Endocrine Heart, Nauka Publishers, Moscow (1997), 242p.
留言 (0)